Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Biomarker Testing Is A Critical Component in Treatment of Gynecologic Cancers

May 25th 2022

Rebecca A. Previs, MD, discusses the role of biomarkers in uterine and endometrial cancers, the standard of care for patients with different biomarkers in uterine cancer, how PARP inhibitors have affected the treatment of ovarian cancer, and the key clinical trials in gynecologic cancers.

FDA Grants Priority Review to Mirvetuximab Soravtansine for FRα-High, Platinum-Resistant Ovarian Cancer

May 23rd 2022

The FDA has accepted and filed a biologics license application for mirvetuximab soravtansine for the treatment of patients with folate receptor alpha–high, platinum-resistant ovarian cancer who have previously received between 1 and 3 systemic therapies.

Monk Breaks Down Recent Advances Across the Gynecologic Cancer Paradigm

May 22nd 2022

Bradley J. Monk, MD, FACS, FACOG, discusses the future of ovarian cancer treatment, ongoing and future trials, as well as combination therapies that may benefit patients with ovarian cancer, cervical cancer, and endometrial cancer.

Pembrolizumab/Chemo With or Without Bevacizumab Has Potential as New SOC in Metastatic Cervical Cancer

May 21st 2022

Nicoletta Colombo, MD, PhD, discusses the practice-changing data to emerge from KEYNOTE-826 and the next steps for the pembrolizumab plus chemotherapy with or without bevacizumab regimen in patients with cervical cancer.

Pembrolizumab Monotherapy Adds Option in MSI-H/dMMR Endometrial Cancer

May 18th 2022

The FDA has approved pembrolizumab in patients with advanced endometrial cancer that is microsatellite instability-high or mismatch repair–deficient and who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.

The Saga of Regional Therapy in the Treatment of Ovarian Cancer

May 17th 2022

Despite numerous well-designed and conducted randomized trials, a definitive answer to the role of specific disease management remains unclear, particularly in the discussions of the optimal role for the regional delivery of cytotoxic chemotherapy in the treatment of patients with ovarian cancer.

Stanford Faculty Break Down Advancements in Women’s Cancer Care

May 13th 2022

Advancements in treatment options across the spectrum on women’s cancers include de-escalating therapy in HER2-positive breast cancer, using tisotumab vedotin-tftv in cervical cancer, shifting therapies to the frontline setting in endometrial cancer, and using checkpoint inhibitors in ovarian cancer.

Navicixizumab/Paclitaxel Combo Demonstrates Early Promise in Platinum-Resistant Ovarian Cancer

May 13th 2022

The addition of navicixizumab to paclitaxel produced encouraging responses with manageable toxicity in patients with platinum-resistant ovarian cancer irrespective of prior treatment with bevacizumab.

Vibostolimab/Pembrolizumab Combo Elicits Antitumor Activity in Metastatic Cervical Cancer

May 11th 2022

Two investigated doses of vibostolimab in combination with pembrolizumab resulted in comparable antitumor activity and safety in patients with locally advanced or metastatic cervical cancer who were naïve to PD-1/PD-L1 inhibitors, regardless of PD-L1 status.

VB10.16 Plus Atezolizumab Elicits Responses in HPV16-Positive Cervical Cancer

May 10th 2022

The first-in-class, off-the-shelf therapeutic cancer vaccine VB10.16 in combination with atezolizumab generated positive responses in heavily pretreated patients with HPV16-positive advanced cervical cancer.

Dr. Monk on the Growing Role of Checkpoint Inhibitors in Cervical Cancer

May 4th 2022

Bradley J. Monk, MD, FACS, FACOG, discusses the growing role of checkpoint inhibitors in cervical cancer.

European Commission Approves Pembrolizumab/Chemotherapy With or Without Bevacizumab for PD-L1+ Metastatic Cervical Cancer

April 29th 2022

The European Commission has granted an approval to the combination of pembrolizumab and chemotherapy, with or without bevacizumab, for the treatment of adult patients with persistent, recurrent or metastatic cervical cancer whose tumors have a PD-L1 combined positive score of 1 or higher.

European Commission Approves Pembrolizumab for Select MSI-H/dMMR Solid Tumors

April 29th 2022

The European Commission has granted an approval to pembrolizumab for the treatment of patients with select microsatellite instability–high or deficient mismatch repair solid tumors.

Neoadjuvant Chemoimmunotherapy Demonstrates Activity in Advanced Ovarian Cancer

April 13th 2022

The addition of durvalumab and tremelimumab to chemotherapy led to encouraging responses and a suitable safety profile as neoadjuvant therapy in patients with advanced ovarian cancer, according to findings from the phase 2 KGOG 3046.

Addition of NG-641 to Nivolumab Under Exploration in Epithelial Tumors

April 12th 2022

The combination of the novel adenoviral vector NG-641 and nivolumab is being investigated in patients in the phase 1a/b NEBULA trial in patients with previously treated metastatic or advanced epithelial tumors.

ZN-c3 Shows Preliminary Efficacy, Safety in Recurrent/Advanced Uterine Serous Carcinoma

April 12th 2022

The investigational Wee1 inhibitor ZN-c3 was found to be safe and to produce a disease control rate of 90.9% and an objective response rate of 27.3% in patients with advanced or recurrent uterine serous carcinoma.

Olaparib Combination Shows Notable Non-Progression Rate in Endometrial Cancer

April 11th 2022

In the ENDOLA trial, olaparib in combination with metronomic cyclophosphamide and metformin showed a significant non-progression rate in patients with recurrent advanced or metastatic endometrial cancer.

Study Reveals Increased Disparities in Cervical Cancer Screening Linked With COVID-19 Pandemic

April 7th 2022

Women of all races and ethnicities who were referred to a colposcopy clinic for cervical cancer screening following an abnormal Pap smear during the COVID-19 pandemic had a higher likelihood of not adhering to their appointment compared with appointment data collected prior to the pandemic.

Matulonis’ Passion Drives Gynecologic Cancer Research Into the Next Era

April 7th 2022

Specialization in oncology research affords investigators the opportunity to dive into tumor biology and uncover unique approaches to care.

Ongoing Clinical Trials for Patients With Endometrial Cancer: Looking Toward the Future

April 5th 2022

Experts highlight key ongoing trials and emerging therapies for patients with endometrial cancer.